Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | POLB | P06746 | 2/20 | 0.42 |
| ▸ | GFER | P55789 | 2/20 | 0.42 |
| ▸ | GAA | P10253 | 1/20 | 0.42 |
| ▸ | ACHE | P22303 | 1/20 | 0.40 |
| ▸ | PDE3B | Q13370 | 1/20 | 0.38 |
| ▸ | PDE3A | Q14432 | 1/20 | 0.38 |
| ▸ | AKR1B1 | P15121 | 4/20 | 0.36 |
| ▸ | CYP3A4 | P08684 | 2/20 | 0.35 |
| ▸ | MAPT | P10636 | 2/20 | 0.35 |
| ▸ | MEN1 | O00255 | 1/20 | 0.35 |
| ▸ | HPGD | P15428 | 1/20 | 0.35 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.35 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.35 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.35 |
| ▸ | CA9 | Q16790 | 1/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL11974270 | 0.83 | POLB (0.44) | POLBGFERGAAACHEPDE3B | |
| SCHEMBL16134098 | 0.83 | POLB (0.44) | POLBGFERGAAACHEPDE3B | |
| SCHEMBL16133970 | 0.81 | PDE3B (0.43) | POLBGFERGAAACHEPDE3B | |
| SCHEMBL1635426 | 0.78 | ACHE (0.50) | POLBGFERGAAACHECYP3A4 | |
| SCHEMBL29793476 | 0.78 | ACHE (0.50) | POLBGFERGAAACHECYP3A4 | |
| Isoespintanol SCHEMBL17442883 | 0.77 | AKR1B1 (0.42) | POLBGFERGAAACHEPDE3B | |
| SCHEMBL7706095 | 0.76 | ACHE (0.48) | POLBGFERGAAACHECYP3A4 | |
| Iodide SCHEMBL8935417 | 0.76 | ACHE (0.48) | POLBGFERGAAACHECYP3A4 | |
| Bromide SCHEMBL8935516 | 0.74 | ACHE (0.46) | POLBGFERGAAACHECYP3A4 | |
| Bromide SCHEMBL8935512 | 0.74 | ACHE (0.46) | POLBGFERGAAACHECYP3A4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9744186-B2 | Substituted gemcitabine aryl amide analogs | NUCORION PHARMACEUTICALS, INC. (US) | 2017-08-29 | — | — | US | disclosed |
| US-20160354399-A1 | SUBSTITUTED GEMCITABINE ARYL AMIDE ANALOGS | THE OHIO STATE UNIVERSITY | 2016-12-08 | — | — | US | disclosed |
| US-9447137-B2 | Substituted gemcitabine aryl amide analogs | NUCORION PHARMACEUTICALS, INC. (US) | 2016-09-20 | — | — | US | disclosed |
| US-20150259375-A1 | SUBSTITUTED GEMCITABINE ARYL AMIDE ANALOGS | THE OHIO STATE UNIVERSITY | 2015-09-17 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20150259375-A1 | SUBSTITUTED GEMCITABINE ARYL AMIDE ANALOGS | TYMP, GMNN, SAMHD1 | POLB 206/4885GFER 3718/4885GAA 122/4885 |
| US-20160354399-A1 | SUBSTITUTED GEMCITABINE ARYL AMIDE ANALOGS | KRAS, NRAS, GMNN | POLB 294/4885GFER 3327/4885GAA 124/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.